Objectives: Assessment of the prognostic role of left ventricular stiffness (LVS) in patients with aortic stenosis (AS) undergoing transcatheter aortic valve implantation (TAVI).
| INTRODUCTION
Transcatheter aortic valve implantation (TAVI) has proven to be a safe and effective technique for aortic valve replacement in patients with aortic stenosis (AS) at high surgical risk.
1,2 However, despite the net hemodynamic improvement observed after TAVI, a high one-year mortality rate (15%-30%) is still observed 3, 4 and nearly 20% of survivors experience limited clinical benefit. 5 AS is associated with left ventricular (LV) remodeling, usually concentric hypertrophy that eventually leads to diastolic dysfunction and increased LV stiffness (LVS). At this stage, decreased longitudinal systolic function is common, as demonstrated by reduced longitudinal strain values and lower stroke volume index (SVi), despite normal ejection fraction (EF). 6, 7 Several studies have identified low SVi before TAVI 8, 9 and the development of moderate-to-severe paravalvular leak (PVL) after TAVI 10, 11 as the main determinants of an adverse outcome. However, there is only limited evidence on the potential prognostic role of diastolic dysfunction and LVS in patients undergoing TAVI. 12 Furthermore, the assessment of diastolic function is generally performed through Doppler parameters which do not directly evaluate LVS (rather reflecting left ventricular filling pressure and relaxation), thus being unable to fully evaluate the diastolic phase. Conversely, the invasive measurement of LV end-diastolic pressure (EDP) allows for the evaluation of the entire end-diastolic pressure-volume relationship (EDPVR) through the identification of a single point of the pressurevolume curve, with the so-called single-beat approach. 13, 14 In the present study, we prospectively calculated the EDPVR and the LVS, defined as the end-diastolic volume (EDV) indexed by body surface area (BSA)
at a standardized EDP of 20 mm Hg (EDVI 20 ).
Aims of our study were (1) to determine the prognostic impact of LVS on 1-year outcome and (2) to define the relationship among LVS, SVi, and PVL in patients with AS undergoing TAVI. clinical comorbidities, of congestive heart failure requiring inotropes, of previous valve surgery, or of associated valvular diseases of more than mild severity. All patients signed a written informed consent before the procedure. Preprocedural operative risk was assessed with the Logistic Euroscore. The TAVI procedure was performed as previously described. 15, 16 All invasive pressure measurements, including LV EDP and transaortic gradients, were performed with a fluid-filled catheter before the procedure and immediately after prosthetic valve implantation. All patients underwent a complete 2D transthoracic echocardiographic study 1-3 days before TAVI and within 5 days after TAVI with a Philips iE33 machine (Philips Inc., Andover, MA, USA). Transthoracic echocardiography was performed according to current recommendations by a trained physician. 17, 18 Particularly, to define the remodeling pattern, we assessed left ventricular mass (LVM) using Devereux formula, to derive LVM indexed (LVMi) by body surface area (BSA) and by height 2.7 (LVMh) and the mass to volume ratio (LVM/EDV). 19 As a measure of global LV load, we calculated the valvuloarterial impedance (Z VA ). Finally, α and β were derived by the following equations:
| METHODS
When invasively measured EDP was higher than 22 mm Hg, the following modified equations were used:
(1) EDP = α×EDV β .
β = log (EDP∕30) log (EDV∕30) . 
BMI, body mass index; BSA, body surface area; CHD, coronary heart disease; EDVI 20 , end-diastolic volume at 20 mm Hg indexed to BSA; NYHA, New York Heart Association. The primary endpoint of this study was one-year all-cause mortality after TAVI. Follow-up was performed through ambulatory visits or through telephone contact with the deceased patients' physicians and/or relatives.
| Statistical analysis
Data are presented as mean ± standard deviation (SD 20 for the prediction of 1-year all-cause mortality was determined with c-statistic in a receiver operating characteristic curve analysis as maximum sum of sensitivity and specificity.
For outcome analysis, Kaplan-Meier survival curves were generated and differences between all-cause mortality were assessed using the log rank test. Statistical significance was assumed when the null hypothesis could be rejected with a P value <.05. The additional value of the independent predictors of 1-year mortality (EDVI 20 respective to PVL) was evaluated with the incremental chi-square test, as previously shown. 22 An interactive stepwise approach was thus performed, where variables were included into the following order: the presence of aortic PVL, impact of EDVI 20 , with the respective chi-square calculated. The incremental prognostic value of the added variable was determined by comparison with the global chi-square calculated at a second step.
A P value <.05 was considered as the required level of significance.
Statistical analysis was performed using a dedicated software package (MedCalc 12.7., MedCalc Software, Mariakerke, Belgium).
| RESULTS
We enrolled 166 patients (64% female; mean age 82.7 ± 5.1 years)
with severe AS at high surgical risk (Logistic Euroscore 17.1% ± 8.2%).
Baseline characteristics of patients are listed in Table 1 . Immediately after TAVI, all invasive hemodynamic parameters were significantly improved (peak-to-peak gradient 66 ± 23 vs 3.0 ± 5.5 mm Hg; P<.0001).
At postprocedural echocardiography, AVAi significantly increased Figure 3 ). Patients with higher LVS had a more pronounced ventricular remodeling before TAVI, compared with patients with lower LVS (Table 4) 
| DISCUSSION
The main findings of the present study are as follows:
• In patients with severe AS and preserved EF, an increased LVS (assessed by EDVI 20 ) is independently associated with a poor outcome.
• LVS is associated with a more advanced LV remodeling pattern and a lower SVi.
• The presence of higher LVS has an incremental negative prognostic impact on 1-year survival over the presence of a moderate-to-severe PVL after TAVI. to decreased longitudinal systolic function. 6, 7 In our study, AS patients with an advanced LV remodeling showed an increased LVS (assessed by EDVI20) and a markedly reduced SVi, despite a normal EF. In this "lowflow/high-gradient" AS group, 26, 27 LVS was associated with higher 1-year mortality, also after adjusting for baseline SVi and for the development of moderate-to-severe PVL after TAVI, both validated prognostic factors in TAVI recipients. Conversely, conventional Doppler parameters of diastolic function (as E/e′, E/A ratio, and DT) were altered but did not help risk stratification in our population with advanced LV remodeling. Probably, this is due to the fact that all these indices are sensitive markers of increased LV filling pressures, but are not able to describe intrinsic myocardial properties. Noteworthy, the average EDVI20 in our study was 54.6 ± 12 mL/m SVi, and a worse outcome. 28, 29 This suggests that in patients with AS, an abnormal diastolic stiffness may represent a marker of intrinsic myocardial dysfunction, which leads to a reduced flow, despite a preserved EF.
T A B L E 3 Cox regression analysis: independent predictors of one-year all-cause mortality
Indeed, in the current study, SVi was associated with LVS also after adjusting for EF, EDD, EDV, and LVMi. In this context, we might speculate that a "bad" LV remodeling phenotype could be associated with an irreversible LV functional impairment, which in turn leads to a dismal outcome after TAVI. This may also explain the lack of clinical benefit observed in nearly 20% of TAVI patients and the still relatively high mortality rate despite the resolution of AS after TAVI. Noteworthy, a high rate of PVL was observed in our population. However, the occurrence of some degree of PVL is common, as previously described, 30 and may reach 93% of cases. 31 Most patients had mild or trivial PVL and this is generally associated with a favorable outcome. In our study, mild PVL occurred in 68% of patients after TAVI, a rate consistent with previous observations, 30, 31 and did not help with risk stratification, as previously described. Conversely, the presence of higher LVS correctly stratifies the short-term prognosis. Moreover, in agreement with previous studies, a moderate-to-severe PVL was associated with a worse outcome. We observed a moderate-to-severe PVL after TAVI in 25% of patients, while in other studies PVL ranges from 0% to 24%. 4, 11, 32 Anyway, despite the not negligible rate of significant PVL reported in our population, one-year all-cause mortality rate was only 12.6%, a value that is inferior to previous findings. 4, 10, 33 Furthermore, the rate of significant PVL did not differ between patients with higher and lower LVS. Interestingly, LVS allows a better stratification also in this group of patients. Indeed, patients with higher LVS and moderate-tosevere PVL had the worst outcome. Finally, LVS (assessed as EDVI 20 ) did not only predict outcome independently, but it also had an incremental prognostic value over the presence of moderate-to-severe PVL.
| Limitations
The major limitation is the monocentric nature and the relatively small patient population. Secondly, the rate of moderate-to-severe PVL was higher than previously observed. 4, 11, 32 One of the possible reasons could be the use of third-generation CoreValve ReValving system for all patients enrolled. In literature, moderate-to-severe PVL seems to be higher with the CoreValve system with respect to balloon-expandable prosthesis. 32 Actually, a standardized method to accurately defining the severity of PVL does not exist, and then a precise quantification by echocardiographic or angiographic often remains challenging.
Anyway, the high rate of PVL observed did not affect the role of LVS in predicting clinical outcome. Then, as we stated, our study investigated only patients receiving the CoreValve self-expandable prosthesis. The results may not be applicable to other TAVI devices. Finally, diastolic stiffness was not assessed invasively with a ventricular conductance catheter; however, previous studies showed a good correlation between invasive and noninvasive measurements. 
| CONCLUSIONS
In patients with AS undergoing TAVI with a self-expandable prosthesis, the presence of an increase LVS, resulting from an advanced LV remodeling, has a dismal impact on 1-year outcome. In addition, such
negative prognostic impact appears to be incremental over the development of a moderate-to-severe PVL. These findings support the opportunity to assess LVS and remodeling pattern before TAVI in order to better stratify the short-term prognosis of TAVI candidates.
DISCLOSURES
None. 
